Modulation of cyptosporidiosis by CD4 levels in chronic diarrhoea HIV/AIDS individuals visiting Tarkwa Municipal hospital, Ghana

Godwin Kwakye-Nuako 1, Johnson Nyarko Boampong 1, Mark Kweku Dong 2, Dorcas Obiri-Yeboah 3, Yeboah Kwaku Opoku 1, 4, Daniel Amoako-Sakyi 3, Kwame Kumi Asare 1, 5, 6*

1 Department of Biomedical and Forensic Sciences, University of Cape Coast, Cape Coast, Ghana
2 Tarkwa Municipal Hospital, Tarkwa, Ghana
3 School of Medical Sciences, University of Cape Coast, Cape Coast, Ghana
4 Northeast Agricultural University, Harbin, China
5 Leading Program, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan
6 Department of Protozoology Institute of Tropical Medicine (NEKKEN), Nagasaki University Sakamoto 1-12-4, Nagasaki 852-8523, Japan

ARTICLE INFO

Article history:
Received 3 Aug 2016
Received in revised form 15 Aug, 2nd revised form 19 Aug, 3rd revised form 22 Aug 2016
Accepted 28 Aug 2016
Available online

Keywords:
CD4
Cryptosporidium
Microsporidium
Cyclospora
Tarkwa
Mining

ABSTRACT

Objective: To investigate the role CD4+ levels play in controlling diarrhea conditions caused by intestinal coccidian infections among HIV/AIDS infected individuals visiting Tarkwa Municipal Hospital.

Methods: Fifty HIV/AIDS infected subjects with diarrhea conditions were enrolled into the study. Stool and blood samples were collected from each in two or three consecutive times to examine intestinal coccidial and microsporidian infections using microscopy and also estimate CD4+ cells using BD FACSCount TM.

Results: Fourteen of the participants had intestinal coccidian or microsporidian representing 28% while 72% of the participants had diarrhea of unknown origin. Cryptosporidium recorded the highest prevalence of 42.56% whilst Cyclospora and Microsporidia equally recorded a prevalence of 28.57%. A significant protection against cryptosporidiosis was observed for CD4+ count above 200 cells/µL ($\chi^2 = 6.522, P = 0.038$), but not cyclosporiasis ($P = 0.233$) or microsporidiosis ($P = 0.060$).

Conclusions: This study has shown that CD4+ cells above 200 cell/µL of blood protect HIV-infected patients from cryptosporidiosis. Standardization of the association between CD4+ cells and diarrhea condition caused by Cryptosporidium species is therefore suggested to serve as an indicator for prompt diagnosis and treatment of HIV-infected individuals with cryptosporidiosis.

1. Introduction

Chronic diarrhea in HIV/AIDS infection has many non-specific etiologies resulting in delayed diagnosis and treatment[1]. The etiological agent can either be infectious or noninfectious[2-6]. The infectious agents are the opportunistic parasites belonging to coccidia or Microsporidia[7-10]. These opportunistic parasites often go undetected in HIV/AIDS with chronic diarrhea. Untreated infections invigorate the clinical condition in HIV/AIDS patients. Cryptosporidium hominis, Cryptosporidium parvum, and Enterocytozoon bieneusi infections are self-limiting in immunocompetent individuals but cause chronic diarrhea in HIV/AIDS patients[11,12]. Chronic diarrhea with persistent opportunistic parasitic infection has been linked to the depletion of CD4+ cells in HIV/AIDS[12-15]. The CD4+ cell depletion is attributed to HIV virus priming the CD8+ T lymphocytes to kill the CD4+ T lymphocytes cells[16-18].

The lower absolute CD4+ cell count has shown to be the risk factor of disseminated pulmonary cryptosporidiosis among cancer patients on immunosuppressive agents with severe or atypical diarrhea in
Kwame Kumi Asare et al./Asian Pac J Trop Dis 2016; 6(10): 770-775

Saudi Arabia[19], however, withdrawal of immunosuppressive agents restored their immunity against enteric protozoa[20].

Although there are several effective treatment and diagnostic tools for opportunistic pathogens in HIV/AIDS[21,22], routine diagnosis and treatment are often ignored at the antiretroviral therapy clinics. This study was conducted to investigate the role CD4+ levels play in controlling diarrhea conditions caused by intestinal coccidian infections among HIV/AIDS infected individuals visiting Tarkwa Municipal Hospital.

2. Material and methods

2.1. Study site

Samples were collected from Tarkwa Municipal Hospital between July 2010 and April 2011. This hospital has an HIV clinic which offers voluntary counselling and testing for the populace. Tarkwa is the capital of Tarkwa-Nsuaem municipal district in the western region of Ghana (Figure 1). The municipality has a population of 90,477 inhabitants of which 34,941 have settled at Tarkwa, the capital city. The majority (about 56%) of the population are youth between the ages of 15 years and 50 years. The municipality is popular for its gold, manganese, iron ore and bauxite mining.

2.2. Ethical approval

The research protocols were reviewed and approved by the Department of Biomedical and Forensic Science Research Board, University of Cape Coast (DBFRB/09/0132) and Medical Administrative Committee of Tarkwa Municipal Hospital. Blood samples were obtained from subjects who had accepted to participate in the study to monitor their immune status in order to determine the appropriate time to put them on antiretroviral therapy.

2.3. Selection of study subjects

The aim of the study was explained to the potential subjects who were either HIV infected or having AIDS and experiencing diarrhea. The subjects who agreed to be part of the study were required to sign an acceptance document before being enrolled into the study. The subjects were required to give at least two to three stool and blood samples any time they experience diarrhea within a space of three months.

2.4. Sample collection

Participants of the study were given at least five 60 mL plastic leak...
proof stool containers with a spoon to collect stool samples prior to visiting the health facility any time they experienced diarrhea. The stool samples were either processed immediately upon collection or stored at −20 °C for a period of 48 h before processing. Five milliliters of capillary blood was taken per visit into ethylene diamine tetraacetic acid anticoagulant tubes for CD4 estimation.

2.5. CD4/CD8 estimation using FACSCount

BD FACSCount CD4/CD3 and CD8/CD8 two-tube format reagent kit (two-tube format): (340167, Becton Dickinson, USA) and FACSCount (software version 1.2) were used for the estimation of CD4+ and CD8+ lymphocytes levels in the sample[23].

2.6. Direct wet mount

One gram of each of the fresh stool samples was emulsified with 2–3 drops of physiological saline, and stained with a drop of Lugol’s iodine. A total of 20 µL of the emulsified stool was transferred onto a microscopic slide and covered with a coverslip. The preparation was observed under the microscope with the 10× and 40× objective lenses.

2.7. Formalin-ethyl acetate concentration method

One gram of faeces with 8 mL of 10% formaldehyde was sieved using gauze into a centrifuge tube containing 4 mL of ethyl acetate. The suspension was mixed thoroughly for 1 min and centrifuged immediately at 1 000 g for 1 min. The supernatant was discarded and the residue resuspended. A few drops were transferred onto microscope slide, covered with coverslip and examined using 10× and 40× objective lenses.

2.8. Modified acid-fast and trichrome staining

Thin stool smears were made from formalin-ethyl acetate concentration and then fixed in methanol for 2–3 min and allowed to air dry. The smears were stained using modified acid-fast and trichrome staining methods as described[24,25].

2.9. Statistical analysis

The data generated were analysed using SPSS version 16. Statistical significance between CD4+ level categories and identified coccidian or microsporidian parasites in stool samples were tested using Pearson Chi-square statistics.

3. Results

In all 50 subjects who were HIV/AIDS infected with recurrent diarrhea had their stool samples and CD4 cells examined at least twice within three months. Thirty six (72%) of the participants had their stool and blood samples examined thrice while the rest of the subjects had their samples examined twice. Each sample examination coincided with diarrhea episodes. All the 23 (46%) of the participants who had low CD4+ cell count at the start of this study were on antiretroviral therapy treatment whereas 54% of the participants were not on antiretroviral therapy treatment but were being monitored at the HIV clinic. In all, 20 (40%) of the participants were males with a mean age of 35.80 years and 30 (60%) of them were females with the mean age of 39.03 years. The age range of the participants were from 21 to 57 years.

A total of 136 stool samples were examined for intestinal coccidia and Microsporidia from 50 participants. Fourteen of the participants had intestinal coccidian or microsporidian representing 28% whilst 72% of the participants had diarrhea of unknown origin. Among the participants with intestinal coccidian or microsporidian infection, 28.57% had Cyclospora and microsporidium each, and 42.86% had Cryptosporidium but no Isospora species was recovered in this study (Figure 2). There were equal occurrences of 50% Cryptosporidium and Cyclospora in both male and female participants. However, females had a higher prevalence (75%) of microsporidium infection.

Figure 2. Prevalence of intestinal coccidian and microsporidian among study subjects.
A: Prevalence of Cyclospora, Cryptosporidium, microsporidian and Isospora among study subjects; B: Coccidian and microsporidian oocysts in stool; a: Cyclospora oocyst in trichrome staining; b: Cryptosporidium oocyst in trichrome staining; c: Microsporidian spores in modified acid-fast staining; d: Microsporidian spores in trichrome staining.
whilst male participants had 25% microsporidium infection (Figure 3). Thirty-six (72%) of the participants had their CD4+ level counted thrice whilst 28% of the participants had their CD4+ level counted only twice. Fifteen (30%) of the participants had CD4+ cell count above 500 cells/mm³ of blood, 12 (24%) had CD4+ cell count 200–499 cells/mm³ and 23 (46%) had CD4+ cell count lower than 200 cells/mm³. The prevalence of Cryptosporidium, Cyclospora, and microsporidium infections were analyzed based on CD4+ cells categories. In all 13 (56.52%) of the participants with CD4+ cell levels lower than 200 cells/mm³ had intestinal coccidian or Microsporidia infections; only 1 (6.67%) of the participants with a CD4+ cell level between 200 and 499 cells/mm³ had Cyclospora infection. Apart from Cyclospora infection, no other intestinal coccidian or Microsporidia infections were seen in CD4+ category 200–499 cells/mm³ or above 500 cells/mm³ of blood. There was a significant difference in Cryptosporidium infection among the CD4+ cells categories ($\chi^2 = 6.522, P = 0.038$) but not in Cyclospora ($P = 0.233$) or microsporidium ($P = 0.060$) (Table 1).

![Figure 3](image-url)  
**Figure 3.** Gender and prevalence of intestinal coccidian and microsporidian among study subjects.

### Table 1  
Test of association between the prevalence of *Cyclospora*, *Cryptosporidium* and *Microsporidium* and CD4+ T-cell counts among study subjects.

| CD4+ T-cell count (cells/µL) | Number of tested | Number of positive (%) | $\chi^2$ | $P$  |
|-----------------------------|------------------|------------------------|---------|------|
| *Cyclospora* spp.           |                  |                        |         |      |
| > 500                       | 15               | 1 (6.7)                | 2.915   | 0.233|
| 200–499                     | 12               | 0 (0.0)                | 0.00    | 1.00 |
| < 200                       | 23               | 3 (13.0)               | 3.35    | 0.069|
| *Cryptosporidium* spp.      |                  |                        |         |      |
| > 500                       | 15               | 0 (0.0)                | 6.522   | 0.038|
| 200–499                     | 12               | 0 (0.0)                | 0.00    | 1.00 |
| < 200                       | 23               | 6 (26.1)               | 10.21   | 0.003|
| *Microsporidium* spp.       |                  |                        |         |      |
| > 500                       | 15               | 0 (0.0)                | 5.626   | 0.060|
| 200–499                     | 12               | 0 (0.0)                | 0.00    | 1.00 |
| < 200                       | 23               | 4 (17.4)               | 5.01    | 0.029|

### 4. Discussion

Diarrhea has become a cardinal feature of HIV/AIDS, affecting up to 90% infected individuals[26,27]. Chronic diarrhea has severe consequences on the quality of health, morbidity, and mortality of HIV-infected patients[1,27]. The etiology of diarrhea in HIV/AIDS is multi-factorial ranging from pathogenic infection to non-pathogenic factors[28,29]. Causes of diarrhea in HIV/AIDS are the profound intestinal coccidian protozoan infections such as *Cryptosporidium*, *Cyclospora*, *Isospora* and *Microsporidium* which naturally cause self-limiting infections in immunocompetent individuals[5,9,11,29]. However, it becomes chronic in HIV/AIDS leading to weight loss, wasting syndrome and finally resulting in acute morbidity and mortality[30]. These opportunistic parasites have an adverse health impact on HIV/AIDS patients, yet no routine diagnosis is performed for clients with diarrhea episodes. The severe complications caused by these opportunistic infections could be prevented with early diagnosis and treatment.

In this study, *Cryptosporidium* is the most frequent diarrheae-causing coccidian in HIV/AIDS followed by *Cyclospora* and *Microsporidium*. Cryptosporidiosis, cyclosporiasis, and microsporidiosis related diarrhea in HIV are worldwide, although their frequencies vary from one geographical area to another[31,32]. This finding is in agreement with several reports that had shown cryptosporidiosis as the most frequent diarrhea condition in HIV/AIDS infections[4,33,34]. Cryptosporidiosis responds to antiretroviral therapy or highly active antiretroviral therapy, however, its effects vary from case to case[35,36]. Cryptosporidiosis can resolve spontaneously or progress to severe and unremitting diarrheal[37]. Contrary, cyclosporiasis causes complication in both the immunocompetent and immunocompromised persons despite its low occurrence in HIV infection compared to cryptosporidiosis[38,39].

The study showed that more female subjects are infected with *Microsporidium* species compared to their male counterparts, whereas, *Cryptosporidium* and *Cyclospora* have similar occurrences in male and female subjects. Anuar et al. showed that microsporidiosis frequently affects females than males which is in agreement with our current data[40]. Other studies have shown that microsporidium infects more males than females contrarily to our findings[41]. The possible reason could be attributed to the frequency of contact with infectious sources. The previous study conducted by Wang et al. did not find any differences between *Cryptosporidium* infection and gender among HIV/AIDS patients with chronic diarrheal[42]. However, the study conducted in Kenya on the risk of *Cryptosporidium* exposure showed that *Cryptosporidium* infection depends on occupation which in turn affects gender[43]. The former which is similar to the current study was designed for internal predisposing factors (immunity) whereas the latter was designed to assess the external predisposing factors (exposure) and *Cryptosporidium* infection. Massoua et al. showed that there is no significant difference between gender and *Cyclospora* infections among immunocompetent individuals with diarrhea episodes which augments the findings of this study[44].

The study showed that there is a significant association between...
CD4+ cell count lower than 200 cells/mm³ and cryptosporidiosis but not cyclosporiasis or microsporidiosis in HIV/AIDS. Cryptosporidiosis can occur at any point in time of HIV infections, but major morbidity and mortality exclusively occur at CD4+ cell counts below 180 cells/mm³ in patients whereas there is spontaneous recovery in patients with higher CD4+ cell counts above this level[45]. HIV/AIDS mortality data from Milwaukee (USA) showed that patients with CD4+ cell counts below 50 cells/mm³ had 73% death rate caused by cryptosporidiosis and 36% death rate in patients with CD4+ cell count ranging from 50 to 200 cells/mm³[46]. The most profound effect of Cryptosporidium infection is the extraintestinal manifestations such as biliary cryptosporidiosis, cryptosporidial pneumonitis and cryptosporidial colitis which are associated with a CD4+ cell count below 100 cells/mm³ are unique to immunocompromised persons. Extraintestinal cryptosporidiosis is resistant to treatment by current anti-cryptosporidial regimens[47]. It is therefore important to promptly diagnose and treat Cryptosporidium infections and other opportunistic pathogens in HIV/AIDS infected individuals to reduce cryptosporidial associated morbidity and mortality.

The limitation of this study was the low sample size which could either underestimate or overestimate the results.

This study has shown that CD4+ cells above 200 cell/μL of blood protect HIV-infected patients from cryptosporidiosis. Here we therefore suggested that standardization of association between CD4+ cells and diarrhea condition caused by Cryptosporidium species could serve as an indicator for prompt diagnosis and treatment of HIV-infected individuals with cryptosporidiosis.

Conflict of interest statement

We declare that we have no conflict of interest.

Acknowledgments

We are grateful to the Department of Biomedical and Forensic Sciences, University of Cape Coast, Tarkwa Municipal Hospital where the work was carried out and also to our participants for making the studies successful.

References

[1] Agholi M, Hatam GR, Motazedian MH. HIV/AIDS-associated opportunistic protozoal diarrhea. AIDS Res Hum Retroviruses 2013; 29(1): 35-41.

[2] Yang Y, Lin Y, Li Q, Zhang S, Tao W, Wan Q, et al. Widespread presence of human-pathogenic Enterocytozoon bieneusi genotype D in farmed foxes (Vulpes vulpes) and raccoon dogs (Nyctereutes procyonoides) in China: first identification and zoonotic concern. Parasitol Res 2015; 114(11): 4341-8.

[3] Adamu H, Petros B, Zhang G, Kassa H, Amer S, Ye J, et al. Distribution and clinical manifestations of Cryptosporidium species and subtypes in HIV/AIDS patients in Ethiopia. PLoS Negl Trop Dis 2014; 8(4): e2831.

[4] Wumba R, Longo-Mbenza B, Menotti J, Mandina M, Kintoki F, Sitiukabanza NH, et al. Epidemiology, clinical, immune, and molecular profiles of microsporidiosis and cryptosporidiosis among HIV/AIDS patients. Int J Gen Med 2012; 5: 603-11.

[5] Kurniawan A, Karyadi T, Dwintasari SW, Sari IP, Yunihastuti E, Djauzi S, et al. Intestinal parasitic infections in HIV/AIDS patients presenting with diarrhoea in Jakarta, Indonesia. Trans R Soc Trop Med Hyg 2009; 103(9): 892-8.

[6] Abdool Karim Q, Abdool Karim S, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996): 1168-74.

[7] Mirjalali H, Mohebali M, Mirhendi H, Gholami R, Keshavarz H, Meamar AR, et al. Emerging intestinal microsporidia infection in HIV(+)/AIDS patients in Iran: microscopic and molecular detection. Iran J Parasitol 2014; 9(2): 149-54.

[8] Gholami R, Gholami S, Emadi-Kouchak H, Abdollahi A, Shahriri M. Clinical characteristic of the HIV/AIDS patients with cryptosporidiosis referring to behavioral diseases Consultation Center, Imam Khomeini Hospital, Tehran in 2013. Iran J Pathol 2016; 11(1): 27-34.

[9] Abu-Akkada SS, El Kerdany ED, Mady RF, Diab RG, Khedr GA, Ashmawy KI, et al. Eucephalitozoon cuniculi infection among immunocompromised and immunocompetent humans in Egypt. Iran J Parasitol 2015; 10(4): 561-70.

[10] Saad AGE, Elkersh WM, Afifi AF, Hawash Y, Shendi SS. Coccidial parasitic infections in liver transplant recipients. Menoufia Med J 2015; 28(3): 635-41.

[11] Krones E, Högenuer C. Diarrhea in the immunocompromised patient. Gastroenterol Clin North Am 2012; 41(3): 677-701.

[12] Becker SL, Vogt J, Knopp S, Panning M, Warhurst DC, Polman K, et al. Persistent digestive disorders in the tropics: causative infectious pathogens and reference diagnostic tests. BMC Infect Dis 2013; 13(1): 37.

[13] Morris A, Norris KA. Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012; 25(2): 297-317.

[14] Joseph SB, Arrildt KT, Swanstrom AE, Schnell G, Lee B, Hoxie JA, et al. Quantification of entry phenotypes of macrophage-tropic HIV-1 across a wide range of CD4 densities. J Virol 2014; 88(4): 1858-69.

[15] Marchetti G, Cozzi-Lepri A, Merlini E, Bellistrì GM, Castagna A, Galli M, et al. Microbial translocation predicts disease progression of HIV-infected antiretroviral-naïve patients with high CD4+ cell count. AIDS 2011; 25(11): 1385-94.

[16] Cooper A, García M, Petrovas C, Yamamoto T, Koup RA, Nabel GJ. HIV-1 causes CD4 cell death through DNA-dependent protein kinase during viral integration. Nature 2013; 498(7454): 376-9.

[17] Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, et al. Immune activation and CD8+ T-cell differentiation towards senescence
in HIV-1 infection. *PLoS Biol* 2004; 2(2): e20.

[18] Février M, Dorgham K, Rebollo A. CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. *Viruses* 2011; 3(5): 586-612.

[19] Sanad MM, Thagfan FA, Al Olayan EM, Almogren A, Al Hammaad A, Al-Mawah A, et al. Opportunistic coccidian parasites among saudi cancer patients presenting with diarrhea: prevalence and immune status. *Res J Parasitol* 2014; 9: 55-63.

[20] Stark D, Barratt JL, van Hal S, Marriott D, Harkness J, Ellis JT. Clinical significance of enteric protozoa in the immunosuppressed human population. *Clin Microbiol Rev* 2009; 22(4): 634-50.

[21] Mead JR, Arrowood MJ. Treatment of cryptosporidiosis. In: *Cryptosporidium: parasite and disease*. Vienna: Springer; 2014, p. 455-486.

[22] Cello JP, Day LW. Idiopathic AIDS enteropathy and treatment of gastrointestinal opportunistic pathogens. *Gastroenterology* 2009; 136(6): 1952-65.

[23] Pattanapanyasat K, Sukapirom K, Kowawisatsat L, Theptai C. New BD FACSClone™ CD4 reagent system for simultaneous enumeration of percent and absolute CD4 T-lymphocytes in HIV-1-infected pediatric patients. *Cytometry B: Clin Cytom* 2008; 74(Suppl 1): S98-106.

[24] Garcia LS, Bruckner DA, Brewer TC, Shimizu RY. Techniques for the recovery and identification of *Cryptosporidium* oocysts from stool specimens. *J Clin Microbiol* 1983; 18(1): 185-90.

[25] Ignatius R, Lehmann M, Miksits K, Regnath T, Arvand M, Engelmann E, et al. A new acid-fast trichrome stain for simultaneous detection of *Cryptosporidium parvum* and *Microsporidial* species in stool specimens. *J Clin Microbiol* 1997; 35(2): 446-9.

[26] Checkley W, White AC, Jaganath D, Arrowood MJ, Chalmers RM, Chen XM, et al. How common is intestinal parasitism in HIV-infected patients in Malaysia. *PLoS One* 2013; 8(8): e71870.

[27] Becker DJ, Oloya J, Ezeamama AE. Household Socioeconomic and demographic correlates of *Cryptosporidium* seropositivity in the United States. *PLoS Negl Trop Dis* 2015; 9(9): e0004080.

[28] Carpenter RD, DuPont HL. Etiology and pharmacologic management of noninfectious diarrhea in HIV-infected individuals in the highly active antiretroviral therapy era. *Clin Infect Dis* 2012; 55(6): 860-7.

[29] Jha AK, Uppal B, Chadha S, Bhatta P, Ghosh R, Aggarwal P, et al. Clinical and microbiological profile of HIV/AIDS cases with diarrhea in North India. *J Pathog* 2012; 2012: 971958.

[30] Kaiser L, Surawicz CM. Infectious causes of chronic diarrhea. *Best Pract Res Clin Gastroenterol* 2012; 26(5): 563-71.

[31] Vyas N, Pathan N, Aziz A. Enteric pathogens in HIV-positive patients with diarrhea and their correlation with CD4+ T-lymphocyte counts. *Trop Parasitol* 2012; 2(1): 29-34.

[32] Putignani L, Menichella D. Global distribution, public health and clinical impact of the protozoan pathogen *cryptosporidium*. *Interdiscip Perspect Infect Dis* 2010; 2010: pii: 753512.